Evidence map›Paper›PMID 40797302›Full record

ArticleBMC genomic data2025

Surviving antibiotic treatment as a gut bacterium: genomic characterization of an Enterobacter cloacae.

Anna Baborski, Stefanie A Barth, Elke Martina Jung, Frank Bloos, Jürgen Rödel, Bettina Löffler, Michael Bauer, Anne Busch

Abstract read
In one paragraph

Article in BMC genomic data, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The Antimicrobial Peptide CRAMP-34 EradicatesAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anna BaborskiDepartment of Anaesthesiology and Intensive Care Medicine, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany.
Stefanie A BarthInstitute of Molecular Pathogenesis, Friedrich-Loeffler-Institut/Federal Research Institute for Animal Health, Naumburger Str. 96a, 07743, Jena, Germany.
Elke Martina JungDepartment of Medical Microbiology, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany.
Frank BloosDepartment of Anaesthesiology and Intensive Care Medicine, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany.
Jürgen RödelInstitute of Microbiology, Friedrich Schiller University Jena, Jena, Germany.
Bettina LöfflerCluster of Excellence Balance of the Microverse, Friedrich Schiller University Jena, Jena, Germany.
Michael BauerDepartment of Anaesthesiology and Intensive Care Medicine, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany.
Anne BuschDepartment of Anaesthesiology and Intensive Care Medicine, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany. Anne.Busch@uni-jena.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enterobacter cloacae complex is a group of common opportunistic pathogens on intensive care units. On intensive care units sepsis is treated with high doses of antibiotics. This treatment does not only eliminate pathogenic bacteria but parts of the microbiome community as well. This leads to an imbalance of the gut microbiome. However, some bacteria can survive such treatment due to certain survival and resistance mechanisms. Not only antibiotic resistance mechanisms but also forming strong communities via biofilm formation promotes cell survival. Here, we investigated the properties of the isolate AT70PIP076 from a sepsis patient treated with piperacillin and tazobactam. After biochemical analysis and MALDI-TOF analysis, the strain was found to be Enterobacter cloacae. In addition to in vitro, antimicrobial susceptibility testing the genome was further investigated in situ regarding antibiotic resistance. Further live/dead staining was performed, and the biofilm formation was investigated using confocal laser microscopy (cLSM). The genome shows the presence of biofilm-associated genes EU554560, bcsABZC_AP010953, ehaB, KF662843, and crl. The understanding of the underlying mechanism of survival of potential pathogens might contribute to elucidate potential treatment options.ObjectivesGenomic analysis of a bacterium that can survive antibiotic treatment within the gut of an antibiotictreated patient to elucidate survival and resistance mechanisms.Data descriptionThe isolate AT70PIP076 was isolated in 2021 from feces collected from a patient treated with Piperacillin and tazobactam. Whole genome DNA was isolated using the Nextera DNA Flex microbial colony extraction protocol and the Nextera Flex DNA preparation kit according to the manufacturer's instructions. Following paired-end sequencing was performed on the MiSeq platform (Illumina, Inc., San Diego, CA, USA) using a 300-cycle MiSeq reagent kit and a read length of 151 bp. Contamination check and identification of 16 S RNA sequences was done by using ContESt16S. The genomic sequence contained 4,988,237 bp and the G + C content is represented at 54.80%. This genome and its associated data set will serve as a useful resource for further analyses.

Indexed as

Anti-Bacterial AgentsEnterobacter cloacaeGenome, BacterialBiofilmsDrug Resistance, BacterialEnterobacteriaceae InfectionsGastrointestinal MicrobiomeGenomicsHumansMicrobial Sensitivity TestsSepsisWhole Genome SequencingAnti-Bacterial AgentsAntibiotic resistanceBiofilmEnterobacter cloacaeSepsis

Identifiers

PMID40797302
PMCPMC12345040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.